95 related articles for article (PubMed ID: 25714451)
1. Development of a [177Lu]BPAMD labeling kit and an automated synthesis module for routine bone targeted endoradiotherapy.
Meckel M; Nauth A; Timpe J; Zhernosekov K; Puranik AD; Baum RP; Rösch F
Cancer Biother Radiopharm; 2015 Mar; 30(2):94-9. PubMed ID: 25714451
[TBL] [Abstract][Full Text] [Related]
2. Formulation, preclinical evaluation, and preliminary clinical investigation of an in-house freeze-dried EDTMP kit suitable for the preparation of 177Lu-EDTMP.
Das T; Sarma HD; Shinto A; Kamaleshwaran KK; Banerjee S
Cancer Biother Radiopharm; 2014 Dec; 29(10):412-21. PubMed ID: 25409337
[TBL] [Abstract][Full Text] [Related]
3. Complexes of low energy beta emitters 47Sc and 177Lu with zoledronic acid for bone pain therapy.
Majkowska A; Neves M; Antunes I; Bilewicz A
Appl Radiat Isot; 2009 Jan; 67(1):11-3. PubMed ID: 18929490
[TBL] [Abstract][Full Text] [Related]
4. Comparative studies on the potential use of
Zakaly HMH; Mostafa MYA; Deryabina D; Zhukovsky M
Int J Radiat Biol; 2020 Jun; 96(6):779-789. PubMed ID: 32043915
[No Abstract] [Full Text] [Related]
5. Production, quality control, biodistribution assessment and preliminary dose evaluation of (177)Lu-PDTMP as a possible bone palliative agent.
Yousefnia H; Jalilian AR; Zolghadri S; Ghannadi-Maragheh M
Nucl Med Commun; 2014 Jan; 35(1):99-107. PubMed ID: 24162837
[TBL] [Abstract][Full Text] [Related]
6. Development of [(90)Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases.
Ogawa K; Kawashima H; Shiba K; Washiyama K; Yoshimoto M; Kiyono Y; Ueda M; Mori H; Saji H
Nucl Med Biol; 2009 Feb; 36(2):129-35. PubMed ID: 19217524
[TBL] [Abstract][Full Text] [Related]
7. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases.
Pandit-Taskar N; Batraki M; Divgi CR
J Nucl Med; 2004 Aug; 45(8):1358-65. PubMed ID: 15299062
[TBL] [Abstract][Full Text] [Related]
8. Preliminary studies on (177)Lu-labeled sodium pyrophosphate (177Lu-PYP) as a potential bone-seeking radiopharmaceutical for bone pain palliation.
Abbasi IA
Nucl Med Biol; 2012 Aug; 39(6):763-9. PubMed ID: 22459337
[TBL] [Abstract][Full Text] [Related]
9. Convenient Formulation of
Guleria M; Das T; Amirdhanayagam J; Shinto AS; Kamaleshwaran KK; Pandian A; Sarma HD; Dash A
Cancer Biother Radiopharm; 2019 Mar; 34(2):67-75. PubMed ID: 30394799
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effects of a 186Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model.
Ogawa K; Mukai T; Asano D; Kawashima H; Kinuya S; Shiba K; Hashimoto K; Mori H; Saji H
J Nucl Med; 2007 Jan; 48(1):122-7. PubMed ID: 17204708
[TBL] [Abstract][Full Text] [Related]
11. Preparation, quality control and biodistribution assessment of ¹⁵³Sm-BPAMD as a novel agent for bone pain palliation therapy.
Rabie A; Enayati R; Yousefnia H; Jalilian AR; Shamsaei M; Zolghadri S; Bahrami-Samani A; Hosntalab M
Ann Nucl Med; 2015 Dec; 29(10):870-6. PubMed ID: 26260999
[TBL] [Abstract][Full Text] [Related]
12. 177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation.
Das T; Chakraborty S; Unni PR; Banerjee S; Samuel G; Sarma HD; Venkatesh M; Pillai MR
Appl Radiat Isot; 2002 Aug; 57(2):177-84. PubMed ID: 12150276
[TBL] [Abstract][Full Text] [Related]
13. 177Lu-EDTMP: a potential therapeutic bone agent.
Ando A; Ando I; Tonami N; Kinuya S; Kazuma K; Kataiwa A; Nakagawa M; Fujita N
Nucl Med Commun; 1998 Jun; 19(6):587-91. PubMed ID: 10234664
[TBL] [Abstract][Full Text] [Related]
14. Labelling of
Iori M; Capponi PC; Rubagotti S; Esposizione LR; Seemann J; Pitzschler R; Dreger T; Formisano D; Grassi E; Fioroni F; Versari A; Asti M
Contrast Media Mol Imaging; 2017; 2017():8160134. PubMed ID: 29097938
[TBL] [Abstract][Full Text] [Related]
15. The use of radioisotopes for palliation of metastatic bone pain.
Gkialas I; Iordanidou L; Galanakis I; Giannopoulos S
J BUON; 2008; 13(2):177-83. PubMed ID: 18555462
[TBL] [Abstract][Full Text] [Related]
16. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions.
Bouchet LG; Bolch WE; Goddu SM; Howell RW; Rao DV
J Nucl Med; 2000 Apr; 41(4):682-7. PubMed ID: 10768569
[TBL] [Abstract][Full Text] [Related]
17. A "mix-and-use" approach for formulation of human clinical doses of
Chakraborty S; Vimalnath KV; Rajeswari A; Chakravarty R; Sarma HD; Radhakrishnan E; Kamaleshwaran K; Shinto AS; Dash A
J Labelled Comp Radiopharm; 2017 Jul; 60(9):410-419. PubMed ID: 28477391
[TBL] [Abstract][Full Text] [Related]
18. Preparation, evaluation, and first clinical use of 177Lu-labeled hydroxyapatite (HA) particles in the treatment of rheumatoid arthritis: utility of cold kits for convenient dose formulation at hospital radiopharmacy.
Chakraborty S; Vimalnath KV; Rajeswari A; Shinto A; Sarma HD; Kamaleshwaran K; Thirumalaisamy P; Dash A
J Labelled Comp Radiopharm; 2014 Jun; 57(7):453-62. PubMed ID: 24966157
[TBL] [Abstract][Full Text] [Related]
19. [177Lu]Lu-DOTA-zoledronate therapy - first application in a patient with primary osseous metastatic bronchial carcinoma.
Kreppel B; Gaertner FC; Ahmadzadehfar H; Khawar A; Roesch F; Kürpig S; Meisenheimer M; Essler M; Bundschuh RA
Nuklearmedizin; 2020 Jun; 59(3):281-283. PubMed ID: 32344437
[No Abstract] [Full Text] [Related]
20. Radiopharmaceuticals: when and how to use them to treat metastatic bone pain.
Paes FM; Ernani V; Hosein P; Serafini AN
J Support Oncol; 2011; 9(6):197-205. PubMed ID: 22055888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
